Елена Вовк - Неалкогольная жировая болезнь печени
- Название:Неалкогольная жировая болезнь печени
- Автор:
- Жанр:
- Издательство:Эксмо
- Год:2018
- Город:Москва
- ISBN:978-5-04-094647-1
- Рейтинг:
- Избранное:Добавить в избранное
-
Отзывы:
-
Ваша оценка:
Елена Вовк - Неалкогольная жировая болезнь печени краткое содержание
Неалкогольная жировая болезнь печени - читать онлайн бесплатно ознакомительный отрывок
Интервал:
Закладка:
74. Nadtochiy S.M., Redman E.K. Mediterranean diet and cardioprotection: the role of nitrite, polyunsaturated fatty acids and polyphenols. Nutrition (Burbank, Los Angeles County, Calif). 2011;27(7–8):733–744. doi:10.1016/j.nut.2010.12.006.
75. Simopoulos A.P. Human requirement for Q-3 polyunsaturated fatty acids. Poult Sei. 2000 Jul; 79(7):961-70.
76. Weber P.C., Leaf A. Cardiovascular effects of omega-3 fatty acids. Atherosclerosis risk factor modification, 1991.
77. Rodriguez-Leyva D., et al. The cardiovascular effects of flaxseed and its omega-3 fatty acid, alpha-linolenic acid. Can J Cardiol. 2010 November; 26(9): 489–496.
78. Leyva D.R., Zahradka P., Ramjiawan B., et al. The effect of dietary flaxseed on improving symptoms of cardiovascular disease in patients with peripheral artery disease: rationale and design of the FLAX-PAD randomized controlled trial. Contemp Clin Trials. 2011; 32: 724–730.
79. Parker H.M., Johnson N.A., Burdon C.A., et al. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012 Apr;56(4):944-51. doi: 10.1016/j.jhep.2011.08.018.
80. Sonne D.P., Knop F.K. Cardiovascular effects of alpha-linolenic acid-a possible role of glucagon-like peptide-1. Exp Biol Med (Maywood). 2013 Oct;238(10):1116-7. doi: 10.1177/1535370213503434.
81. Gundermann K.-J., Gundermann S., Drozdzik M., Mohan Prasad V. Essential phospholipids in fatty liver: a scientific update. Clinical and Experimental Gastroenterology. 2016;9:105–117. doi:10.2147/CEG.S96362.
82. Kidd P.M. Cell membranes, endothelia, and atherosclerosis — the importance of Phosphatidylcholine. Altern Med Rev 1996;1:148–167.
83. Un C., Zheng X., Tan Z. et al. Clinical Observation on Polyene Phosphatidyl Choline and Metformin in the Treatment of Type 2 Diabetes and Non-alcoholic Fatty Liver Disease // Clin Focus. — 2008. — Vol. 23, N 17. — P. 1272–3.
84. Yin Kong. Observation for curative effect of Essentiale in treatment of fatty liver caused by diabetes mellitus // Med J Qilu. — 2000. — Vol. 15. — P. 277–8.
85. Guo S. Observation on treatment of fatty liver disease with polyene phosphatidylcholine // China Foreign Med J. 2007. Vol. 5, Issue 10.
86. Kuntz E., Kuntz H.-D. Гепатология: учебное пособие и атлас. 3-е изд. — Springer Press, Heidelberg 2008; глава 40., С. 896.
87. Sas et al. Beneficial influence of polyunsaturated Phosphatidylcholine enhances functional liver condition and liver structure in patients with Nonalcoholic steatohepatitis Journal of Hepatology 2013; 58: S549 (EASL congress 2013) & Hepatol Int (2013) 7 (Suppl 1):S71.
88. Singal A.K., Jampana S.C., Weinman S.A. Liver Int. 2011; 31(10): 1432–1448.
89. OkiyamaW. et al. J Hepatol. 2009 Jun; 50(6): 1236–1246.
90. MazzellaN., Ricciardi L.M., Mazzotti A., Marchesini G. The role of medications for the management of patients with NAFLD. Clin Liver Dis. 2014 Feb;18(l):73–89. doi: 10.1016/j. cld.2013.09.005.
91. Hallsworth K., Avery L., Trenell M.I. Targeting Lifestyle Behavior Change in Adults with NAFLD During a 20-min Consultation: Summary of the Dietary and Exercise Literature. Curr Gastroenterol Rep. 2016 Mar;18(3):ll. doi: 10.1007/S11894-016-0485-1.
Интервал:
Закладка:
